Start­up mak­ing Cas9 proxy for gene edit­ing gets $55M to de­vel­op tools/soft­ware

Boul­der-based start­up In­scrip­ta — which you might re­mem­ber as the com­pa­ny that dis­cov­ered a new CRISPR en­zyme… and then gave it away for free — just land­ed $55.5 mil­lion in a Se­ries C round.

In­scrip­ta made head­lines last De­cem­ber when it an­nounced the com­pa­ny had un­earthed what its call­ing “MAD7,” an al­ter­na­tive en­zyme to CAS9 that could be used to ed­it DNA. Hav­ing a proxy for Cas9 can get more com­pa­nies jump­ing in­to the gene edit­ing game, In­scrip­ta’s CEO Kevin Ness tells me.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER